Senate Delay in Confirming HHS Secretary Could Stall Biden’s Healthcare Plans

Senate Delay in Confirming HHS Secretary Could Stall Biden’s Healthcare Plans

Five days after the inauguration of President Joe Biden, the Senate has not yet scheduled confirmation hearings for Xavier Becerra, Biden’s nominee for Secretary of the Department of Health and Human Services (HHS)...

January 25, 2021 5:52 PM

Woodcock to Take Helm While Biden Considers FDA Commissioner Choice

Woodcock to Take Helm While Biden Considers FDA Commissioner Choice

Under the Biden administration, Center for Drug Evaluation and Research (CDER) director and FDA veteran Janet Woodcock, M.D., will be tapped to serve as the acting commissioner of the FDA as of Jan. 20...

January 18, 2021 2:06 PM

Despite Strain on Resources During Pandemic, CDER Approves 53 Novel Drugs in 2020

Despite Strain on Resources During Pandemic, CDER Approves 53 Novel Drugs in 2020

When considering all of the COVID-19 challenges the FDA faced in 2020, it is noteworthy that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year...

January 11, 2021 4:13 PM

Marketing Tax, Pricing Limits, Other Measures May Pass as Add-ons to Omnibus Bills

Marketing Tax, Pricing Limits, Other Measures May Pass as Add-ons to Omnibus Bills

The just-enacted COVID-19 relief bill may be a harbinger of what is to come in 2021 for drug pricing and marketing tax proposals, according to Coalition for Healthcare Communication Executive Director Jon Bigelow...

 

January 5, 2021 10:02 AM

Upcoming Event

12/16/20 Webinar: What’s next for the FDA in the Biden administration?

Dec. 16, 2020, 12-1 pm ET

The FDA entered 2020 with a new Commissioner, then soon faced unusual scientific challenges—and unprecedented political attacks—as it worked to cope with the COVID-19 pandemic. Yet, even as its credibility took some hits, the FDA has moved forward aggressively to establish a streamlined process for evaluating COVID-19 vaccines and drugs, and is on track to approve a high number of new molecular entities for other indications.

What’s next for the FDA under a Biden administration? Join us for the insights of Nancy Bradish Myers, president of Catalyst Healthcare Consulting and former Senior Strategic Advisor in the FDA Commissioner’s office. Who will be the next Commissioner, and what will his or her priorities be? Where will the agency fit in the Biden’s plans to combat COVID-19? What can the FDA do to rebuild its credibility? What lessons does the pandemic hold for the drug approval process? What will be in the next PDUFA legislation?

  • Webinar: Wednesday, Dec. 16, 12-1 pm Eastern time
  • Faculty: Nancy Bradish Myers, president, Catalyst Healthcare Consulting
  • Zoom link to be provided to registrants
  • Tuition: Only $75 (from member companies) or $90 (from non-member companies)
  • If uncertain on membership, please see our list of member companies.
  • Online registration open now—see below.

Don’t miss this inside look at an agency with profound impact on our industry!

For further information, contact jbigelow@cohealthcom.org.

 

 

 

Read More +

About Us

CHC

CHC

The Coalition for Healthcare Communication is an organization that promotes the free exchange of scientific and medical information. It is essential that healthcare professionals and the general public receive truthful, accurate information regarding pharmaceuticals, medical products and devices, and patient care.

In addition to white papers and other documents published by the Coalition, you can also find relevant information on current healthcare and health economics issues, as well as policy positions published by government agencies and other professional organizations.